Molecular targeted therapy of glioblastoma by Le Rhun, Emilie et al.








Molecular targeted therapy of glioblastoma
Le Rhun, Emilie ; Preusser, Matthias ; Roth, Patrick ; Reardon, David A ; van den Bent, Martin ; Wen,
Patrick ; Reifenberger, Guido ; Weller, Michael
Abstract: Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor
cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence
increases with age, males are more often affected. Beyond rare instances of genetic predisposition and
irradiation exposure, there are no known glioblastoma risk factors. Surgery as safely feasible followed
by involved-field radiotherapy plus concomitant and maintenance temozolomide chemotherapy define the
standard of care since 2005. Except for prolonged progression-free, but not overall survival afforded by
the vascular endothelial growth factor antibody, bevacizumab, no pharmacological intervention has been
demonstrated to alter the course of disease. Specifically, targeting cellular pathways frequently altered in
glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of
rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor
(EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant
compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or
poor tolerability and safety. Yet, uncommon glioblastoma subsets may exhibit specific vulnerabilities
amenable to targeted interventions, including, but not limited to: high tumor mutational burden, BRAF
mutation, neurotrophic tryrosine receptor kinase (NTRK) or fibroblast growth factor receptor (FGFR)
gene fusions, and MET gene amplification or fusions. There is increasing interest in targeting not only the
tumor cells, but also the microenvironment, including blood vessels, the monocyte/macrophage/microglia
compartment, or T cells. Improved clinical trial designs using pharmacodynamic endpoints in enriched
patient populations will be required to develop better treatments for glioblastoma.
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Abstract: Glioblastomas are intrinsic brain tumors thought to originate 
from neuroglial stem or progenitor cells. More than 90% of glioblastomas 
are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases 
with age, males are more often affected. Beyond rare instances of genetic 
predisposition and irradiation exposure, there are no known glioblastoma 
risk factors. Surgery as safely feasible followed by involved-field 
radiotherapy plus concomitant and maintenance temozolomide chemotherapy 
define the standard of care since 2005. Except for prolonged progression-
free, but not overall survival afforded by the vascular endothelial 
growth factor antibody, bevacizumab, no pharmacological intervention has 
been demonstrated to alter the course of disease. Specifically, targeting 
cellular pathways frequently altered in glioblastoma, such as the 
phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target 
of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or 
epidermal growth factor receptor (EGFR) gene amplification or mutation, 
have failed to improve outcome, likely because of redundant compensatory 
mechanisms, insufficient target coverage related in part to the blood 
brain barrier, or poor tolerability and safety. Yet, uncommon 
glioblastoma subsets may exhibit specific vulnerabilities amenable to 
targeted interventions, including, but not limited to: high tumor 
mutational burden, BRAF mutation, neurotrophic tryrosine receptor kinase 
(NTRK) or fibroblast growth factor receptor (FGFR) gene fusions, and MET 
gene amplification or fusions. There is increasing interest in targeting 
not only the tumor cells, but also the microenvironment, including blood 
vessels, the monocyte/macrophage/microglia compartment, or T cells. 
Improved clinical trial designs using pharmacodynamic endpoints in 
enriched patient populations will be required to develop better 
treatments for glioblastoma. 
 
Suggested Reviewers: Olivier Chinot 
























Please consider for publication as an Invited Review in Cancer Treatment Reviews 
the enclosed manuscript entitled " Molecular Targeted Therapy of Glioblastoma ". 
 









 Most glioblastomas are not “single pathway” diseases easily amenable to 
targeted therapy. 
 The core pathways altered in glioblastoma are challenging for targeted drug 
design. 
 Molecular genetic profiling, e.g. by large-scale DNA and RNA sequencing, 
may identify druggable molecular alterations in subsets of glioblastomas. 
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Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or 
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase 
(IDH)-wildtype tumors. Incidence increases with age, males are more often affected. 
Beyond rare instances of genetic predisposition and irradiation exposure, there are no 
known glioblastoma risk factors. Surgery as safely feasible followed by involved-field 
radiotherapy plus concomitant and maintenance temozolomide chemotherapy define 
the standard of care since 2005. Except for prolonged progression-free, but not 
overall survival afforded by the vascular endothelial growth factor antibody, 
bevacizumab, no pharmacological intervention has been demonstrated to alter the 
course of disease. Specifically, targeting cellular pathways frequently altered in 
glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B 
(AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) 
pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, 
have failed to improve outcome, likely because of redundant compensatory 
mechanisms, insufficient target coverage related in part to the blood brain barrier, or 
poor tolerability and safety. Yet, uncommon glioblastoma subsets may exhibit specific 
vulnerabilities amenable to targeted interventions, including, but not limited to: high 
tumor mutational burden, BRAF mutation, neurotrophic tryrosine receptor kinase 
(NTRK) or fibroblast growth factor receptor (FGFR) gene fusions, and MET gene 
amplification or fusions. There is increasing interest in targeting not only the tumor 
cells, but also the microenvironment, including blood vessels, the 
monocyte/macrophage/microglia compartment, or T cells. Improved clinical trial 
designs using pharmacodynamic endpoints in enriched patient populations will be 






Glioblastoma is an intrinsic brain tumor that may occur at any age and is thought to 
originate by genetic alterations affecting neuroglial stem or progenitor cells [1]. 
Incidence increases steadily with age. Median age at diagnosis is in the range of 65 
years, and males are approximately 1.7-fold more often affected than females. Young 
age and good performance status are therapy-independent positive prognostic 
factors. 
The updated WHO classification from 2016 [2] separates two major types of 
glioblastoma based on mutations in the isocitrate dehydrogenase (IDH) 1 or 2 genes, 
with IDH-wildype glioblastomas accounting for more than 90% of the cases. 
Histologically, glioblastomas are mitotically active tumors characterized by 
microvascular proliferation or necrosis or both as distinctive morphologic features of 
WHO grade IV. According to recent specifications of the consortium to inform 
molecular and practical approaches to CNS tumor taxonomy (cIMPACT) [3], 
molecular diagnostic detection of glioblastoma-associated genetic alterations, 
specifically epidermal growth factor receptor (EGFR) gene amplification, combined 
whole chromosome 7 gain and whole chromosome 10 loss (+7/−10), or telomerase 
reverse transcriptase (TERT) promoter mutation also allow for the diagnosis of 
IDH-wildtype glioblastoma despite the absence of WHO grade IV histological 
features. In contrast, astrocytic gliomas carrying an IDH mutation also may exhibit 
typical histological features of glioblastoma, but typically are associated with a more 
favorable clinical course and hence may no longer be classified as glioblastoma in 
up-coming revisions of the WHO classification. This review thus is focussed on the 
common IDH-wildtype tumors. The 2016 WHO classification [2] has maintained giant 
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cell glioblastoma and gliosarcoma as histological variants of IDH-wildtype 
glioblastoma, while, epithelioid glioblastoma was newly introduced as a provisional 
variant characterized by BRAFV600E mutation in up to 50% of cases [4], although more 
recent data did not identify distinct molecular profiles in these tumors [5]. While 
assigning a tumor to any of these variants has no clinical relevance in terms of 
tailoring standard treatment today [6], detection of BRAFV600E mutation in malignant 
gliomas including epithelioid glioblastomas may assume clinical relevance in terms of 
targeted therapy with mutant BRAF inhibitors (see below). 
Besides histological variants, large-scale genetic and epigenetic profiling studies 
allowed for the distinction of several molecular subgroups of IDH-wildtype 
glioblastomas that are characterized by distinct DNA methylation patterns associated 
with characteristic mutational and expression profiles [7] [8] [9]. Up to seven molecular 
subgroups of IDH-wildtype glioblastoma have been identified by DNA methylation 
profiling, with the receptor tyrosine kinase (RTK) 1 and 2 subgroups as well as the 
mesenchymal subgroup being most common [9]. To date, distinction of these 
molecular subgroups is of limited relevance in terms of treatment, but this may change 
when future studies reveal subgroup-specific therapeutic vulnerabilities. 
 
 
Current standard of care 
 
Surgery as safely feasible followed by involved field radiotherapy in combination with 
concomitant and up to six maintenance cycles of temozolomide chemotherapy 
constitute the standard of care for the majority of patients with newly diagnosed 
glioblastoma [6] [10]. Except for tumor-treating fields [11], no other therapeutic 
intervention has been shown to prolong overall survival in the newly diagnosed setting. 
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All glioblastomas eventually progress, and standards of care at recurrence are less 
well defined. A small proportion of patients with localized recurrence are offered 
second surgery or re-irradiation, but neither of these interventions has been shown to 
prolong survival. Another course of alkylating chemotherapy, mostly the nitrosourea 
compound, lomustine, is the most broadly used intervention at recurrence and also 
constitutes the control arm in recent randomized trials in recurrent glioblastoma [12]. 
Yet, neither lomustine nor any other systemic treatment nor tumor-treating fields [13] 
have been shown to be superior to placebo or best supportive care in a randomized 
trial. 
 
Targeted therapy for glioblastoma: focus on MGMT promoter methylation 
 
Benefit from alkylating agent chemotherapy in glioblastoma is largely limited to 
patients whose tumors show aberrant CpG methylation of the promoter region of the 
O6-methylguanine DNA methyltransferase (MGMT) gene. MGMT promoter 
methylation has been established as a predictive biomarker for benefit from 
temozolomide, although firmly only in the newly diagnosed setting [14] [15]. The 
AVAREG trial assessing fotemustine and bevacizumab appeared to confirm this 
predictive value also for a nitrosourea compound in the recurrent setting [16]. 
However, the REGOMA trial (see below), which also provided data on, albeit locally 
determined, MGMT status did not confirm a predictive value of MGMT promoter 
methylation for benefit from lomustine compared to regorafenib [17]. Since several 
large controlled trials with central MGMT testing have confirmed a strong prognostic 
role of MGMT promoter methylation in recurrent glioblastoma patients treated with 
temozolomide [18] or lomustine [12] [19], the potential predictive role of the MGMT 





An emerging area of interest in cancer therapy, notably glioblastoma, is the 
repurposing of drugs that are already approved for other indications, based on 
assumptions of biochemical or metabolic features that might confer glioma cell 
sensitivity to such drugs. Importantly, retrospective analyses of survival associations 
of all these drugs need to be interpreted with caution and should be considered 
hypothesis-generating only. This is because it is difficult to control for comorbidities 
that led to the administration of these drugs, dosing was never standardized and not 
optimized for demonstrating anti-tumor activity, and data collection was typically 
limited to landmark analyses, but not cumulative dosing. 
 
Anti-epileptic drugs 
Despite decades of research, no conclusive evidence to support a survival-promoting 
activity of anti-epileptic drugs in brain tumor patients has been obtained. Mainly based 
on histone deacetylase inhibitory activity seen at high concentrations in vitro and 
putative differentiation-inducing activity, valproic acid has attracted particular interest. 
The observation of longer survival of patients treated with valproic acid in the EORTC 
26981 trial [20] was not confirmed in an analysis of subsequent larger clinical trial 
populations [21], but the combination of valproic acid with temozolomide 
chemoradiotherapy continues to be explored [22]. Levetiracetam has been proposed 
to decrease the level of MGMT in glioblastoma [23], but no association with favorable 
outcome was seen in a large secondary analysis of clinical trial data [21]. Finally, after 
significant interest in the role of glutamatergic signaling affecting neurotransmission in 
the biology of glioblastoma, the initial excitement on the AMPA receptor antagonist, 
talampanel, subsided when it became clear that single arm phase II studies often 
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generate signals interpreted as promising, but are not predictive of success in 
randomized phase III settings [24] (see below). 
 
Metformin 
This anti-diabetic drug has been advanced as an adjunct to glioblastoma treatment 
because of presumed modulatory effects on metabolism, notably lowering glucose 
availability, suppression of insulin-like growth-factor signaling, and specifically 
inhibition of AMP-activated protein kinase. Yet, current evidence from pooled 
retrospective analyses of clinical trial data does not support the view that metformin 






The majority of clinical trial approaches focusing on glioblastoma-intrinsic targets 
address oncogenic signaling via tyrosine receptor kinases, cell cycle control and 
susceptibility to apoptosis induction. 
 
Tyrosine kinase receptor pathways 
 
Epidermal growth factor receptor (EGFR) 
EGFR is one of most prominent oncogenes in IDH-wildtype glioblastoma. It is 
overexpressed in approximately 60% of tumors, and more than 40% exhibit EGFR 
gene amplification. A particular deletion mutation referred to as EGFRvIII or 
delta-EGFR is found in 25% of tumors and is of particular interest since it is 
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constitutively active and a potential neoantigen (Table 1). Numerous studies have 
failed to demonstrate single agent activity of EGFR tyrosine kinase inhibitors in 
unselected patient populations and small biological endpoint studies have raised 
concerns that these drugs may not be able to suppress pathway activity even if they 
reach the tumor tissue [26] [27]. Other approaches have used EGFR or EGFRvIII 
expression rather than EGFR pathway activity as a target: these include the vaccine, 
rindopepimut, which produced a survival signal when combined with bevacizumab in 
EGFRvIII-positive recurrent glioblastoma (NCT01498328), but failed in phase III (ACT 
IV) in newly diagnosed disease [28]. Similarly, the antibody drug conjugate, 
depatuxizumab mafodotin, consisting of the EGFR antibody ABT-806 linked to 
monomethyl auristatin F, appeared to be active in combination with temozolomide in 
recurrent EGFR-amplified glioblastoma [29], but showed no activity in newly 
diagnosed glioblastoma when combined with standard temozolomide 
chemoradiotherapy (NCT02573324). The ACT IV trial results showed a striking loss of 
EGFRvIII expression at recurrence in both groups of the trial, suggesting that 
EGFRvIII expression is unstable. These observations of unstable target expression 
also cast doubt on the likelihood of success of chimeric antigen receptor (CAR) T cells 
or bispecific T-cell engaging antibodies targeting EGFRvIII [30] [31]. In contrast, 




The PI3K/mTOR pathway is one of the almost inevitably altered molecular pathways 
in IDH-wildtype glioblastoma, as a consequence of loss of tumor suppressor 
phosphatase and tensin homolog on chromosome ten (PTEN) function, activating 
mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
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(PIK3CA), the gene encoding the catalytic subunit p110 alpha (p110α), and in 
phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1), encoding the p85α 
regulatory subunit. Yet, like in other types of cancer, it has turned out to be 
challenging to translate this extensive knowledge on pathway alteration into clinical 
benefit, although there is a long tradition of targeting the PI3K pathway in 
glioblastoma.  
As early as 2005, the lack of activity of the mTOR inhibitor, temsirolimus (CCL-779), 
was demonstrated at least when used as a single agent in recurrent glioblastoma [34]. 
It was also observed at this time that the toxicity profile was unfavorable in this patient 
population. More recently, in a similar setting but enrolling patients predicted to be 
enriched for active PI3K signaling, the pan-PI3K inhibitor, buparlisib was found to be 
essentially inactive. This trial included a phase 0-like biological endpoint cohort. A 
subset of patients exhibited reduced levels of phosphorylated AKTS473 in the tumor 
tissue as a direct read-out of PI3K inhibition, but suppression of down-stream 
pS6S235/236 was less pronounced, demonstrating insufficient overall pathway inhibition 
by tolerable doses of buparlisib [35].  
PI3K/mTOR pathway inhibition has also been explored in the newly diagnosed setting, 
either in combination with radiotherapy and temozolomide [36] or instead of 
temozolomide in patients with MGMT promoter-unmethylated glioblastoma [37]. Both 
trials concluded absence of an efficacy signal and both confirmed the relatively poor 
tolerability of mTOR inhibitors in this setting, at least compared with temozolomide. 
In summary, it seems that the PI3K/AKT/mTOR pathway is overall too promiscuous, 
resulting in non-favorable tolerability and safety profiles upon pharmacological 
inhibition. Moreover, well designed clinical trials have indicated that currently available 
agents may be insufficient to inhibit the target adequately at doses that are tolerated 
by patients. One may speculate that even those tumors that are in principle sensitive 
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to target inhibition will rapidly develop escape pathways, circumventing the block of 
the PI3K pathway. Future efforts will have to employ more potent agents or will have 
to rely on combinatorial strategies, the development of which, however, probably 
requires a deeper understanding of how this pathway interacts with other pathways 
that are likely to be altered in glioblastoma. 
 
MET 
The MET gene encodes the receptor for hepatocyte growth factor, also known as 
scatter factor, and has been attributed a major role in the migration and invasiveness 
of glioma cells, notably in response to irradiation, inhibition of angiogenesis, and 
hypoxia [38]. It is commonly expressed in glioblastoma, often at high levels, but not a 
major mutational target (Table 1). Proof of concept for a role of MET amplification was 
obtained in a single patient with recurrent glioblastoma treated with crizotinib [39], but 
not in a second published case [40]. However, neutralizing the ligand appeared to 
have no impact on disease progression [41]. Blocking the receptor using the single 
arm antibody, onartuzumab [42] or cabozantinib, a tyrosine kinase inhibitor of MET, 
VEGFR2 and AXL, in patients without or with pre-exposure to anti-angiogenic agents 
[43] [44] resulted in a modest efficacy signal in recurrent disease. MET fusion genes 
have been detected in a minor subset of pediatric glioblastoma and have been linked 
to response to crizotinib in one patient [45]. 
 
Fibroblast growth factor receptor (FGFR) 
FGFR are commonly expressed in glioblastomas, but relevance as a potential target 
for intervention is probably limited to patients with rare tumors exhibiting FGFR-TACC 
fusions [46]. Despite several ongoing efforts in this area, there is little data available in 
the public domain. One stable disease and one minor response were reported in two 
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patients with FGFR3-TACC3-positive recurrent glioblastoma patients treated with the 
oral pan-FGFR kinase inhibitor, erdafitinib [47]. 
 
BRAF mutation 
BRAF, a member of the Raf family of kinases, feeds into the MAP kinase/ERK 
signaling pathway that promotes proliferation. Activating BRAF mutations, in particular 
the BRAFV600E missense mutation, are found in several tumor types and have been 
confirmed to be druggable molecular lesions, notably in metastatic melanoma [48]. 
Early studies and individual case reports indicated that glial tumors exhibiting BRAF 
mutations may also respond to pharmacological BRAF inhibition, although their 
efficacy seems modest at best in BRAFV600E-mutant glioblastoma [49] [50] [51]. 
 
Neurotrophic tyrosine receptor kinases (NTRK) 
NTRK are encoded by three different genes, NTRK1, NTRK2 and NTRK3. Genomic 
rearrangements in NTRK genes resulting in gene fusions may trigger activation of 
oncogenic TRK signaling. The prevalence of NTRK gene fusions in glioblastoma 
appears to be low [52], and larger studies are required to determine whether agents 
like larotrectinib or entrectinib are also active in NTRK fusion-positive glioblastoma 
[53]. 
 
Cell cycle control and apoptosis regulating pathways 
 
The retinoblastoma (pRB) pathway 
The pRB cell cycle control pathway is altered in the majority of IDH-wildtype 
glioblastomas due to homozygous CDKN2A/B deletion, CDK4 or CDK6 amplification, 
or RB1 gene alterations (Table 1). This pathway is also required for the growth of 
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normal cells which may largely explain why its therapeutic targeting has remained 
challenging, not only in glioblastoma. The only completed phase II trial targeting this 
pathway in glioblastoma using palbociclib was disappointing [54], but patients enrolled 
in this trial represented a negative selection, as indicated by the short overall survival 
(Table 2). 
TG02 is a multi-CDK inhibitor mainly targeting CDK9, but not CDK4/6, and acts 
independently of the cell cycle control pathway involving CDK4/6 to suppress the 
transcription of multiple short-lived survival genes. TG02 is currently being explored in 
clinical trials in recurrent and in newly diagnosed glioblastoma (NCT02942264, 
NCT03224104). 
 
The p53 pathway 
The TP53 tumor suppressor gene is among the best and longest studied genes in 
glioblastoma. Since the key function of its gene product, p53, is to arrest cells in G0/1 
or to trigger apoptosis in response to genotoxic stress, restoring p53 function by 
various approaches has been extensively studied. Yet, drugs aimed at facilitating 
refolding of mutant proteins into wildtype conformation have not been successful, but 
efforts focusing on neutralizing MDM2 and MDM4 for patients with glioblastomas that 
are deficient in p53 function as a consequence of MDM2 or MDM4 gene amplification 
are in progress ([55] and NCT03107780). 
 
TERT promoter mutation 
TERT promoter mutations are the most common molecular alteration in IDH-wildtype 
glioblastoma [8] [56]. They affect two mutation hotspots that create new Ets 
transcripton factor-binding sites and increase TERT transcription and thereby TERT 
activity supporting immortalization of tumor cells [57]. Nevertheless, TERT promoter 
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mutation has not become a major pharmacological target for cancer therapy yet. 
Eribulin, known as an inhibitor of tubulin polymerization, has been proposed to exert 
TERT inhibitory activity in glioblastoma models, justifying its clinical exploration [58]. 
 
Proteasome 
The proteasome is a complex cellular machinery with several enzymatic activities 
involved in the degradation and recycling of cellular protein. Altered proteasome 
activity has emerged as a potential vulnerability of cancer cells and resulted in the 
development of drugs like bortezomib that have also been tested in recurrent 
glioblastoma [59] [60]. The brain-penetrant pan-proteasome inhibitor, marizomib, is 




Microenvironmental targets - Angiogenesis 
 
Vascular endothelial growth factor (VEGF) 
 
The detection of VEGF as a major mediator of angiogenesis in glioblastoma, at a time 
when conventional cancer treatments like radiotherapy and chemotherapy appeared 
to have reached their limits, triggered substantial efforts to establish anti-angiogenesis 
as a treatment paradigm in glioblastoma (Table 2). Based on high radiological 
response rates and encouraging survival outcomes in uncontrolled trials [61 ][62], 
bevacizumab achieved approval for recurrent glioblastoma in many parts of the world, 
but its effects on tumor biology and growth dynamics beyond what can be detected by 
neuroimaging remained controversial. It has remained challenging to identify 
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subgroups of glioblastoma patients that experience prolonged survival when treated 
with bevacizumab [63] [64],  although there are glioblastoma models where VEGF 
may even be a survival factor [65]. Phase III trials in newly diagnosed and recurrent 
disease demonstrated prolonged PFS but consistently no OS benefit, although 
approximately 30% cross-over to bevacizumab was observed in these trials [12] [66] 





Integrins are cell surface molecules that integrate signals from cell to cell and 
extracellular matrix to cell and are involved in essential cellular processes such as 
adhesion, migration, invasion and angiogenesis. Specific subtypes of integrins are 
present in glioblastomas and their vasculature [69]. The results of a series of largely 
uncontrolled clinical trials were interpreted to justify a phase III trial on cilengitide in 
patients enriched for MGMT promoter methylated glioblastomas [70] [71]. Altogether, 
these trials did not provide any robust safety or efficacy signal using cilengitide as a 
lead compound for integrin inhibition, but efforts to employ tumor specific integrin 
expression as a target continue. 
 
Transforming growth factor (TGF)-β 
 
TGF-1/2 as the major representatives of a family of related proteins have been 
considered for decades as key molecules responsible for glioblastoma-mediated 
immunosuppression. However, this protein family is promiscuous in that it is involved 
in almost all physiological and pathological processes. Despite promising data 
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obtained with various modes of TGF-β inhibition in different animal models, clinical 
translation of TGF-β targeting using TGF-β2-specific antisense oligonucleotides [72] 
or tyrosine kinase inhibitors targeting TGF-β receptor II (ALK5) such as galunisertib 
[73] has remained unsuccessful. The introduction of TGF-β receptor inhibitors into the 
clinic has also remained challenging because of dose-limiting toxicity, e.g, to the 
cardiac and intestinal system, potentially preventing adequate target coverage in the 
tumor. 
 
Programmed cell death protein (PD)-1 
The development of neutralizing antibodies to immune checkpoint molecules has 
dominated the field of cancer immunotherapy. Notably antibodies preventing the 
engagement of PD-1 on T cells by is major ligand, PD-L1, expressed on tumor cells, 
or on host cells have attracted marked interest. Yet, despite major advances in the 
treatment of various solid tumors with immune checkpoint inhibition, e.g., melanoma 
or non-small cell lung cancer, immune checkpoint inhibition has not been successful 
in glioblastoma, with the exception of single cases of encouraging responses in 
patients with tumors with high mutational burden due to germ line mutations affecting 
DNA repair [74]. In contrast, large randomized clinical trials of nivolumab versus 
bevacizumab in recurrent glioblastoma (CheckMate 143) [75] or of nivolumab versus 
temozolomide, both in combination with radiotherapy, in MGMT promoter 








The failure of several targeted agents for glioblastoma in late clinical development 
illustrates that most glioblastomas are not even close to being a single pathway-driven 
disease that would be amenable to targeted therapy. There is a need for improved 
clinical trial design and an early inclusion of control arms in phase II settings that allow 
to arrive at meaningful go/no-go decisions for further clinical development. 
Furthermore, platform trials exploring multiple compounds in parallel would in theory 
accelerate drug development. EORTC has developed the SPECTA (Screening 
Cancer Patients for Efficient Clinical Trial Access) platform [76], but this approach has 
not yet been applied to glioblastoma. Innovative clinical trial concepts such as AGILE 
(Adaptive Global Innovative Learning Environment for Glioblastoma) and INSIGhT 
(Individualized Screening Trial of Innovative Glioblastoma Therapy) propose multiple 
arms that can be enlarged or terminated early in a dynamic manner according to their 
probability of success which requires continuous monitoring [77]. Such trials may 
speed drug development significantly, but their success will ultimately depend on 
whether active compounds are tested in well selected patients. Another, not mutually 
exclusive approach would assign patients to clinical trial arms based upon molecular 
profiling in real time. While such clinical trial concepts are overall innovative and 
promising, there are certain caveats [55]. Molecular testing needs to be done quickly 
enough to allow patient treatment in adequate time, algorithms to rank the molecular 
lesions found need to be in place, and pharmaceutical companies need to be 
motivated to collaborate in early phases of drug development. The only randomized 
effort to demonstrate a superiority of treatment allocation based on molecular testing 
over standard of care, the French SHIVA trial, comes from the non-neuro-oncology 
area and failed to demonstrate overall benefit [78], (but profiling techniques have 
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Figure 1. Candidate molecular pathways amenable to targeted interventions in 
glioblastoma. 
 
Figure 2. Selected current strategies of targeted therapy for glioblastoma. A, 
EGFR; B, PI3K/AKT/mTOR; C, MET, D, FGFR; E, BRAF; F, NTRK; G, VEGF; H, 




Table 1. Candidate target molecules for molecular therapy of IDH wildtype glioblastoma 
 
Target Biological function Significance in glioblastoma Selected references 
    
Glioblastoma-intrinsic targets    
    
Epidermal growth factor receptor 
(EGFR) 
Proliferation, invasion, resistance to 
apoptosis induction 
Amplification in 40-50%, including 
EGFRvIII mutation in half of these, 10-20% 
overexpression without amplification 
Brennan et al. 2013 [8], Felsberg et al. 
2017 [33] 
    
PI3K/AKT/mTOR Metabolism, proliferation, migration Almost uniformly activated pathway due to 
loss of PTEN function or activating mutations 
in PIK3CA or PIK3R1 
Brennan et al. 2013 [8] 
    
MET Migration, invasion, wound healing Overexpression, rarely amplification (5%) Brennan et al. 2013 [8], Kwak et al. 2015 
[79] 
    
FGFR Proliferation FGFR transforming acidic coiled-coil 
(TACC) gene fusions (3%) and very 
rarely activating mutations 
Singh et al., 2012 [46], Di Stefano et al. 
2015 [47] 
    
BRAF Proliferation BRAFV600E mutations in up to 50% of 
epithelioid glioblastomas, otherwise rare 
Korshunov et al. 2018 [5] 
    
NTRK Proliferation NTRK gene fusions detected in 1-2% Ferguson et al. 2018 [52] 
    
CDK4/6 or CDKN2A/B or RB Cell cycle progression Pathway often disrupted, because of CDK4/6 
amplification (15%), CDKN2A/B loss (50%) 
or RB mutation (10%) 
Brennan et al. 2013 [8] 
    
P53 Cell cycle progression and apoptosis 
induction 
Mutation or deletion (35%) or neutralization 
by MDM2/4 amplification (20%) 
Brennan et al. 2013 [8] 
    
TERT Proliferation, cellular longevity Enhanced expression resulting from promoter Brennan et al. 2013 
Table(s)
mutation (90%) [8] 
    
Microenvironmental targets    
    
Vascular endothelial growth factor 
(VEGF) 
Blood vessel formation Angiogenesis triggered by hypoxia, 
potentially survival factor for subsets of 
glioblastomas 
Plate et al. 1994 [80], Szabo et al. 2016 
[65] 
    
Integrins Adhesion, migration, adhesion, activation 
of TGF- pathway 
v integrins are expressed in blood vessels 
and tumor cells 
Roth et al. 2013 [69] 
    
TGF-β Pleiotropic cytokine involved in most 
biological processes 
Immunosuppression, migration, invasion, 
angiogenesis 
Frei et al. 2015 [81] 
    
PD-L1 Immune checkpoint, limiting T cell 
activation 
Expression levels in glioblastoma including 
tumor microenvironment remain 
controversial 
Berghoff et al. 2015 [82], Nduom et al. 
2016 [83] 


















Table 2. Selected phase II and III trials of targeted therapy in glioblastoma 
 




Enrichment Design Primary 
endpoint 
Response PFS OS Conclusions 
          
Glioblastoma-
intrinsic targets 
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Weller et al. 2017 
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inactive in newly 
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(86) versus TMZ 






OS ABT-414 plus 





















          
PI3K/AKT/mTOR          
Chang et al. 2005 
[34]  
Temsirolimus Recurrent (43) None Single arm 
phase II 
PFS-6 2 PR PFS-6 
2% 
ND Temsirolimus is 
inactive as single 
agent 
Ma et al. 2015 [36] Everolimus Newly diagnosed 
(104), plus 
TMZ/RTTMZ 
None Single arm 
phase II 




median OS: 15.8 




Wick et al. 2016 [37]  Temsirolimus Newly diagnosed, 
temsirolimus plus 





































PFS-6 None PFS-6 
8% 
9.8 months Buparlisib is 
inactive as single 
agent 
          
MET          
Wen et al. 2011 [41] Rilotumumab Recurrent (60), 
rilotumumab at 10 
or 20 mg/kg 
None Single arm 
phase II 
ORR None PFS (months) 
10 mg/kg: 1.0 
20 mg/kg: 1.0 
OS (months) 
10 mg/kg: 6.5 
20 mg/kg: 5.4  
Rilotumumab is 
inactive  













1 CR, 11 PR 
bevacizumab 
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ORR None, 3 SD in 
6 patients 
  BRAF inhibition 
in gial brain 
tumors deserves 
further study 
          
CDK4/6 or 
CDKN2A/B or RB 
         
Taylor et al. 2018 Palbociclib Recurrent (22) RB1-positive Single arm PFS-6  Median PFS 5 Median OS 15 Palbociclib is 
[54] by immune-
histochemistry 
phase II weeks weeks inactive as single 
agent 
          
Proteasome          




Recurrent (34) None Single arm 
phase II 
PFS-6 1 PR PFS-6: 0% Median OS 3.2 
months 
No indication to 
further study this 
combination 
Kong et al. 2018 [59] Bortezomib Recurrent (24) None Single arm 
phase II 
OS  Median PFS 6.2 
months 





          
Multi-kinase 
inhibition 
         
Lee et al. 2016 [85] Vandetanib
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Wen et al. 2018 [44] Cabozantinib
2
 Recurrent, without 
prior anti-
angiogenic therapy 
(34 at 140 mg/d, 
118 at 100 mg/d)) 
None Single arm 
phase II 




Median OS 7.7 
and 10.4 months 
Cabozantinib is 
inactive as single 
agent 
Cloughesy et al. 
2018 [43] 




None Single arm 
phase II 
ORR 3 PR PFS-6: 8.5% Median OS 4.6 
months 
Cabozantinib is 
inactive as single 
agent 
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Microenvironmental 
targets 
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Kreisl et al. 2009 
[61] 
Bevacizumab Recurrent (48) None Single arm 
phase II 
PFS-6 1 CR, 16 PR PFS-6 29% OS 7.2 months Bevacizumab is 
active 
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plus RT 12.1 
RT 12.2 












Recurrent (42) None Single arm 
phase II 
PFS-6 7 PR PFS-6 8% OS 9.1 months Aflibercept is 
inactive 
          
Batchelor et al. 2010 
[88] 
Cediranib Recurrent (31) None Single arm 
phase II 
PFS-6 8 PR PFS 3.9 months OS 7.6 months Cediranib 
warrants further 
study 
Batchelor et al. 2013 
[68] 
Cediranib Recurrent, 
cediranib (131) or 
cediranib plus 






PFS Cediranib 1 
CR, 17 PR 
cediranib plus 
lomustine 2 













Cediranib is not 
superior to 
lomustine and 
does not prolong 
survival in 
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None Single arm 
phase II 
PFS  PFS 8 months OS 16.1 months Cilengitide 
warrants further 
study 
Nabors et al. 2012 
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(46) dose 
Stupp et al. 2014 [71] Cilengitide Newly diagnosed, 
TMZ/RTTMZ 









OS  PFS (months) 
control 7.9 
cilengitide 10.6 




Nabors et al. 2015 
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Reardon et al. 2018 
[92] 2018 
Trebananib Recurrent, 
trebananib (11) or 
trebananib plus 
bevacizumab (37) 
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Wick et al. 2010 [93]  Enzastaurin Recurrent, 
enzastaurin (266) 























PFS-6  PFS-6 54% OS 15 months Enzastaurin is 
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Brandes et al. 2016 Galunisertib Recurrent, None Randomized OS galunisertib PFS (months) OS (months) Galunisertib is 






















          
Glutamate 
receptors 
         
Iwamoto et al. 2010 
[95]  
Talampanel Recurrent (22) None Single arm 
phase II 
PFS-6 1 PR PFS-6 5% OS 3 months Talampanel is 
inactive in this 
setting 
Grossmann et al. 
2009 [24]  
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phase II 
OS   OS 18.3 months Tamlampanel 
may be further 
evaluated 
          
CD95 ligand          
Wick et al. 2014 [96] APG-101 Recurrent, RT (26) 
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Reardon et al. 2017 
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Nivolumab Recurrent, 























tumors who are 
not on steroids 
          
 
1inhibits VEGFR2, EGFR, RET 
2inhibits VEGFR2, MET, AXL 
3inhibits VEGFR1-3, TIE2, KIT, RET, RAF1, BRAF, PDGFR, FGFR, CSF1R 
 







Table 3. Outlook on improved drug development in glioblastoma. 
Limitations and challenges Solutions 
Molecular testing not standardized and not reimbursed Centralization, implementation into guidelines and proactive dialog with health care 
providers  
Patient selection Avoid selecting last-line patients and focus on biomarker-enriched patient 
populations 
Insufficient drug development strategies Early proof-of-concept (window of opportunity studies) with pharmacodynamic and 
biological endpoints and inclusion of glioblastoma patients in basket trials for tumors 
with defined molecular alterations 
Administrational barriers impeding international cooperations Parallel trials and efforts to increase public awareness in order to change legislation 
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